surpass-cvot tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full trial results: https://nej.md/4qd5rLx π‘ New insight in diabetes
Pay in 4 interest-free payments of $6.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Sep 1 - Sep 6
























